myEDIT-B

First-in-class Blood Test for the Differential Diagnosis of Bipolar Disorder and Unipolar Depression

myEDIT-B is a CE marked IVD medical device, designed as an aid to diagnosis for clinicians to facilitate and optimise the differentiation of unipolar and bipolar depression and their diagnosis.

The Benefits of myEDIT-B Test

- ✓ Effective, simple and rapid diagnosis
- ✓ Easier announcement of the diagnosis, and better therapeutic alliance
- ✓ Better-directed therapeutic choices in complex clinical situations
- ✓ Reduced suffering for patients and their families

« I'm excited that in my lifetime we will finally have a reliable, precision psychiatry diagnostic tool for bipolar disorders. »

David J. Kupfer, M.D.

Advisor for ALCEDIAG since 2014, in reference to myEDIT-B

DSM-5 Task Force Chair

Distinguished Professor Emeritus of Psychiatry University of Pittsburgh School of Medicine

Diagnosing Mood Disorders

Mental health experts report that diagnosing mood disorders is a complex, empirical and lengthy process that requires high levels of expertise. In particular, the differentiation between depression and bipolar disorder is said to be the most stringent diagnostic need still unmet, representing a significant burden to individuals and society. Indeed, symptoms may be similar and clinical evaluations currently used may fail to effectively differentiate between them, as illustrated by these figures:

300 M depressed patients worldwide

Up to 40% of them may actually be suffering from undiagnosed bipolar disorder

Mean time for bipolar disorder diagnosis is **8 years**

Sources: WHO, Angst et al. 2011, Ghaemi et al. 1999

myEDIT-B is Based on RNA Editing

RNA editing is an epigenetic mechanism, which consists in the substitution at precise locations on the RNA of an adenosine by an inosine, leading to the modifications of key functions like synaptic transmission. RNA editing is often reported to make the link between neuroinflammation and psychiatry. ALCEDIAG has conducted over 10 years of R&D in RNA editing, AI and neurosciences, and has demonstrated the value of theses technologies for mental health diagnosis.

myEDIT-B is a clinically validated test with an internal and external validation procedure reporting a sensitivity and specificity over 80%.

The clinical studies involved fully independent international cohorts with several hundred patients.

N. Salvetat et al., *Journal of Affective Disorder*, 2024

myEDIT-B in Practice

my**EDIT-B** is a qualitative In Vitro Diagnostic test (CE-IVD) intended for differentiating bipolar disorder from unipolar depression as an aid to the diagnostic process.



1 & 2 Under medical prescription, collection of patient's blood sample in a SYNLAB laboratory. Targeted RNA sequencing of a panel of 8 biomarkers, using next generation sequencing

3 Data processing using ALCEDIAG's algorithm.

4 & 5 Transmission of myEDIT-B result in the form of a report to the prescribing clinician by SYNLAB laboratory

This myEDIT-B brochure is published by ALCEDIAG - June 2024

my**EDIT-B** is an in vitro diagnostic medical device developed by ALCEDIAG and distributed by Synlab medical biology laboratories.

contact@alcediag-alcen.com
www.alcediag-alcen.com | www.synlab.fr